ABSTRACT
Xymedon (1-(ß-oxyethyl)-4,6-dimethyl-1,2-dihydro-2-oxopyrimidine), a regeneratory and wound-healing drug, exhibited hepatoprotective activity in laboratory animals with experimental toxic hepatitis. Oral drug reduced the severity of toxic involvement of the liver induced by CCl4 and reduced animal mortality. Xymedon promoted recovery of the blood biochemical parameters characterizing the liver status.
Subject(s)
Chemical and Drug Induced Liver Injury/drug therapy , Liver/drug effects , Protective Agents/pharmacology , Pyrimidines/pharmacology , Alanine Transaminase/metabolism , Animals , Animals, Outbred Strains , Aspartate Aminotransferases/metabolism , Blood Glucose/metabolism , Body Weight/drug effects , Carbon Tetrachloride , Chemical and Drug Induced Liver Injury/metabolism , Chemical and Drug Induced Liver Injury/pathology , Liver/metabolism , Liver/pathology , Mice , RatsABSTRACT
The paper is concerned with the problems of technical equipment of standard clinico-diagnostic laboratories (CDL) in this country. The authors suggest a mathematic model that may minimize expenditures for laboratory studies. The model enables the following problems to be solved: to issue scientifically-based recommendations for technical equipment of CDL; to validate the medico-technical requirements for newly devised items; to select the optimum types of uniform items; to define optimal technical decisions at the stage of the design; to determine the lab assistant's labour productivity and the cost of some investigations; to compute the medical laboratory engineering requirement for treatment and prophylactic institutions of this country.
